Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57799 | 1.00 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL1419721 | 1.00 | SCN4A (0.61) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL22229209 | 0.98 | SCN4A (0.59) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL7757109 | 0.98 | SCN4A (0.59) | SCN4ATACR1 | |
| Hydrochloric Acid SCHEMBL56787 | 0.98 | SCN4A (0.59) | SCN4ATACR1 | |
| SCHEMBL12789473 | 0.88 | SCN4A (0.53) | SCN4ATACR1 | |
| SCHEMBL90024 | 0.84 | SCN4A (0.48) | SCN4ATACR1 | |
| SCHEMBL19312226 | 0.84 | SCN4A (0.48) | SCN4ATACR1 | |
| SCHEMBL90002 | 0.84 | SCN4A (0.48) | SCN4ATACR1 | |
| SCHEMBL2782707 | 0.83 | SCN4A (0.68) | SCN4ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | claimed |
| US-7825151-B2 | Hexahydro-cyclooctyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | claimed |
| US-20090215850-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-27 | — | — | US | claimed |
| US-20080234347-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | US | claimed |
| US-20080076814-A1 | Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | claimed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | claimed |
| EP-0776883-A1 | Adduct salts of substituted benzylamine and a process for optically resolving them | Ajinomoto Co., Inc. (JP) | 1997-06-04 | — | — | EP | claimed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4680265-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | Viking Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| EP-4143185-B1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638446-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-0776883-A1 | Adduct salts of substituted benzylamine and a process for optically resolving them | Ajinomoto Co., Inc. (JP) | 1997-06-04 | — | — | EP | disclosed |
| EP-0750622-A1 | ALPHA-AMINOPHOSPHONATES AND PROCESSES FOR THEIR PREPARATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-01-02 | — | — | EP | disclosed |
| EP-0719789-A1 | Process of producing alpha-L-aspartyldipeptide amide derivatives | Ajinomoto Co., Ltd. (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5508463-A | ENANTIOMERICALLY PURE INTERMEDIATES | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| EP-0691346-A1 | Novel aspartyldipeptide derivatives and sweetener | Ajinomoto Co., Inc. (JP) | 1996-01-10 | — | — | EP | disclosed |
| WO-1995025111-A1 | α-AMINOPHOSPHONATES AND PROCESSES FOR THEIR PREPARATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215850-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | CNR2, CNR1, NPY4R | SCN4A 413/4885TACR1 116/4885 |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | SCN4A 1191/4885TACR1 127/4885 |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | SCN4A 4079/4885TACR1 3318/4885 |
| US-20080234347-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | CNR2, CNR1, NPY4R | SCN4A 413/4885TACR1 116/4885 |
| US-20080076814-A1 | Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators | CNR1, CNR2, FAAH | SCN4A 1439/4885TACR1 223/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | SCN4A 3906/4885TACR1 4764/4885 |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | CLK1, CLK2, CLK3 | SCN4A 4378/4885TACR1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.